Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

In Vivo Assessment of Antibody-Dependent Enhancement of Influenza B Infection.

Rao GK, Prell RA, Laing ST, Burleson SCM, Nguyen A, McBride JM, Zhang C, Sheinson D, Halpern WG.

Toxicol Sci. 2019 Jun 1;169(2):409-421. doi: 10.1093/toxsci/kfz053.

PMID:
30796434
2.

Physiology of the Neonatal Gastrointestinal System Relevant to the Disposition of Orally Administered Medications.

Neal-Kluever A, Fisher J, Grylack L, Kakiuchi-Kiyota S, Halpern W.

Drug Metab Dispos. 2019 Mar;47(3):296-313. doi: 10.1124/dmd.118.084418. Epub 2018 Dec 19.

PMID:
30567878
3.

Resolution of unexpected pregnancy-related findings in a rat embryofetal development and toxicokinetic study of monoclonal antibodies specific for hCMV.

Katavolos P, Prell R, Zane D, Deng R, Halpern W.

Birth Defects Res. 2018 Nov 1;110(18):1347-1357. doi: 10.1002/bdr2.1402. Epub 2018 Oct 31.

PMID:
30381912
4.

Applying a weight of evidence approach to the evaluation of developmental toxicity of biopharmaceuticals.

Rocca M, Morford LL, Blanset DL, Halpern WG, Cavagnaro J, Bowman CJ.

Regul Toxicol Pharmacol. 2018 Oct;98:69-79. doi: 10.1016/j.yrtph.2018.07.006. Epub 2018 Jul 24. Review.

PMID:
30009863
5.

Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys.

Prell RA, Dybdal N, Arima A, Chihaya Y, Nijem I, Halpern W.

Toxicol Sci. 2018 Sep 1;165(1):186-197. doi: 10.1093/toxsci/kfy141.

PMID:
29893934
6.

Use of Severity Grades to Characterize Histopathologic Changes.

Schafer KA, Eighmy J, Fikes JD, Halpern WG, Hukkanen RR, Long GG, Meseck EK, Patrick DJ, Thibodeau MS, Wood CE, Francke S.

Toxicol Pathol. 2018 Apr;46(3):256-265. doi: 10.1177/0192623318761348. Epub 2018 Mar 12.

PMID:
29529947
7.

Regulatory Forum Opinion Piece: Review of FDA Draft Guidance Testicular Toxicity-Evaluation during Drug Development Guidance for Industry.

Hukkanen RR, Halpern WG, Vidal JD.

Toxicol Pathol. 2016 Oct;44(7):927-30. doi: 10.1177/0192623316656416. Epub 2016 Jun 29.

PMID:
27357192
8.

Scientific and Regulatory Policy Committee Points to Consider Review: Inclusion of Reproductive and Pathology End Points for Assessment of Reproductive and Developmental Toxicity in Pharmaceutical Drug Development.

Halpern WG, Ameri M, Bowman CJ, Elwell MR, Mirsky ML, Oliver J, Regan KS, Remick AK, Sutherland VL, Thompson KE, Tremblay C, Yoshida M, Tomlinson L.

Toxicol Pathol. 2016 Aug;44(6):789-809. doi: 10.1177/0192623316650052. Epub 2016 May 27.

9.

Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy.

Prell RA, Halpern WG, Rao GK.

Int J Toxicol. 2016 May;35(3):263-73. doi: 10.1177/1091581815625596. Epub 2016 Jan 18.

PMID:
26786669
10.

Combined administration of RG7652, a recombinant human monoclonal antibody against PCSK9, and atorvastatin does not result in reduction of immune function.

Gelzleichter TR, Halpern W, Erwin R, Baruch A, Leabman M, Forrest AS, Satterwhite CM, Peng K, Chilton J, Stevens D.

Toxicol Sci. 2014 Aug 1;140(2):470-80. doi: 10.1093/toxsci/kfu093. Epub 2014 May 20.

PMID:
24848798
11.

Integrated and translational nonclinical in vivo cardiovascular risk assessment: gaps and opportunities.

Berridge BR, Hoffmann P, Turk JR, Sellke F, Gintant G, Hirkaler G, Dreher K, Schultze AE, Walker D, Edmunds N, Halpern W, Falls J, Sanders M, Pettit SD.

Regul Toxicol Pharmacol. 2013 Feb;65(1):38-46. doi: 10.1016/j.yrtph.2012.09.007. Epub 2012 Oct 5.

PMID:
23044254
12.

Stems to GEMs: impact of stem cell technology on engineered animal models.

Halpern W, McArthur M, Galbreath E, Uhl E, Buck W, Whitley E; American College of Veterinary Pathologists Intersociety Experimental Pathology Committee.

Vet Pathol. 2011 Sep;48(5):1041-3. doi: 10.1177/0300985811413093.

PMID:
21865606
13.

Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.

Morford LL, Bowman CJ, Blanset DL, B√łgh IB, Chellman GJ, Halpern WG, Weinbauer GF, Coogan TP.

Birth Defects Res B Dev Reprod Toxicol. 2011 Aug;92(4):359-80. doi: 10.1002/bdrb.20305. Epub 2011 Jul 18. Review.

PMID:
21770023
14.

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.

Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM, Klein J, Halpern W, Miceli R, Kumm E, Fox NL, Czuczman MS.

Br J Cancer. 2010 Dec 7;103(12):1783-7. doi: 10.1038/sj.bjc.6605987. Epub 2010 Nov 16.

15.

Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directions.

Leach MW, Halpern WG, Johnson CW, Rojko JL, MacLachlan TK, Chan CM, Galbreath EJ, Ndifor AM, Blanset DL, Polack E, Cavagnaro JA.

Toxicol Pathol. 2010 Dec;38(7):1138-66. doi: 10.1177/0192623310382559. Epub 2010 Oct 6.

PMID:
20926828
16.

Trail receptors: targets for cancer therapy.

Humphreys RC, Halpern W.

Adv Exp Med Biol. 2008;615:127-58. doi: 10.1007/978-1-4020-6554-5_7. Review.

PMID:
18437894
17.

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.

Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J.

Lung Cancer. 2008 Jul;61(1):82-90. doi: 10.1016/j.lungcan.2007.12.011. Epub 2008 Feb 5.

PMID:
18255187
18.

Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.

Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, Barrett M, Judson I, Kaye S, Fox NL, Halpern W, Corey A, Calvert H, de Bono J.

Clin Cancer Res. 2007 Oct 15;13(20):6187-94.

19.

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A, Cohen RB.

J Clin Oncol. 2007 Apr 10;25(11):1390-5. Erratum in: J Clin Oncol. 2007 Oct 10;25(29):4701.

PMID:
17416859
20.
21.

Osteostat/tumor necrosis factor superfamily 18 inhibits osteoclastogenesis and is selectively expressed by vascular endothelial cells.

Nardelli B, Zaritskaya L, McAuliffe W, Ni Y, Lincoln C, Cho YH, Birse CE, Halpern W, Ullrich S, Moore PA.

Endocrinology. 2006 Jan;147(1):70-8. Epub 2005 Sep 22.

PMID:
16179414
22.

Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.

Melder RJ, Osborn BL, Riccobene T, Kanakaraj P, Wei P, Chen G, Stolow D, Halpern WG, Migone TS, Wang Q, Grzegorzewski KJ, Gallant G.

Cancer Immunol Immunother. 2005 Jun;54(6):535-47. Epub 2004 Dec 8.

PMID:
15592670
23.

Retrospective analysis of implant survival and the influence of periodontal disease and immediate placement on long-term results.

Evian CI, Emling R, Rosenberg ES, Waasdorp JA, Halpern W, Shah S, Garcia M.

Int J Oral Maxillofac Implants. 2004 May-Jun;19(3):393-8.

PMID:
15214224
24.

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.

Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L, Sturm B, Poortman C, Minter RR, Dobson CL, Williams E, Carmen S, Smith R, Roschke V, Hilbert DM, Vaughan TJ, Albert VR.

Arthritis Rheum. 2003 Nov;48(11):3253-65.

25.

Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys.

Halpern W, Riccobene TA, Agostini H, Baker K, Stolow D, Gu ML, Hirsch J, Mahoney A, Carrell J, Boyd E, Grzegorzewski KJ.

Pharm Res. 2002 Nov;19(11):1720-9.

PMID:
12458679
26.

Cromakalim and pinacidil dilate small mesenteric arteries but not small cerebral arteries.

McCarron JG, Quayle JM, Halpern W, Nelson MT.

Am J Physiol. 1991 Aug;261(2 Pt 2):H287-91.

PMID:
1908639
27.

In vitro methodology for resistance arteries.

Halpern W, Kelley M.

Blood Vessels. 1991;28(1-3):245-51. Review.

PMID:
1825797
29.

Potassium dilates rat cerebral arteries by two independent mechanisms.

McCarron JG, Halpern W.

Am J Physiol. 1990 Sep;259(3 Pt 2):H902-8.

PMID:
2168682
30.

Pre-existing level of tone is an important determinant of cerebral artery autoregulatory responsiveness.

Osol G, Osol R, Halpern W.

J Hypertens Suppl. 1989 Sep;7(4):S67-9.

PMID:
2809808
31.

Myogenic responses are independent of the endothelium in rat pressurized posterior cerebral arteries.

McCarron JG, Osol G, Halpern W.

Blood Vessels. 1989;26(5):315-9. No abstract available.

PMID:
2635067
33.

Asymmetry of responses to norepinephrine in perfused resistance arteries.

Tesfamariam B, Halpern W.

Eur J Pharmacol. 1988 Jul 26;152(1-2):167-70.

PMID:
3208831
34.
35.
36.

Spontaneous vasomotion in pressurized cerebral arteries from genetically hypertensive rats.

Osol G, Halpern W.

Am J Physiol. 1988 Jan;254(1 Pt 2):H28-33.

PMID:
3337256
37.

Modulation of adrenergic responses in pressurized resistance arteries by flow.

Tesfamariam B, Halpern W.

Am J Physiol. 1987 Nov;253(5 Pt 2):H1112-9.

PMID:
3688255
38.
39.

Synthetic atrial natriuretic factor does not dilate resistance-sized arteries.

Osol G, Halpern W, Tesfamariam B, Nakayama K, Weinberg D.

Hypertension. 1986 Jul;8(7):606-10.

PMID:
2941373
40.

Resistance vessels in hypertension.

Halpern W, Osol G.

Prog Clin Biol Res. 1986;219:211-23. Review.

PMID:
3538026
41.

Myogenic properties of cerebral blood vessels from normotensive and hypertensive rats.

Osol G, Halpern W.

Am J Physiol. 1985 Nov;249(5 Pt 2):H914-21.

PMID:
4061668
42.

Effects of perfusion and endothelium on the reactivity of isolated resistance arteries.

Tesfamariam B, Halpern W, Osol G.

Blood Vessels. 1985;22(6):301-5. No abstract available.

PMID:
4084685
43.
44.
45.

Effects of two doses of methylphenidate on cross-situational and borderline hyperactive children's evoked potentials.

Klorman R, Salzman LF, Bauer LO, Coons HW, Borgstedt AD, Halpern WI.

Electroencephalogr Clin Neurophysiol. 1983 Aug;56(2):169-85.

PMID:
6191948
46.
47.

Biochemical and mechanical properties of resistance arteries from normotensive and hypertensive rats.

Brayden JE, Halpern W, Brann LR.

Hypertension. 1983 Jan-Feb;5(1):17-25.

PMID:
6848464
48.
49.

Potassium depolarization of adrenergic varicosities in resistance arteries from SHR and WKY rats.

Whall CW Jr, Havlik RJ, Halpern W, Bohr DF.

Blood Vessels. 1983;20(1):23-33.

PMID:
6821708
50.

Increased vascular catecholamine sensitivity and alpha-adrenergic receptor affinity in female and estrogen-treated male rats.

Colucci WS, Gimbrone MA Jr, McLaughlin MK, Halpern W, Alexander RW.

Circ Res. 1982 Jun;50(6):805-11. No abstract available.

PMID:
6282493

Supplemental Content

Loading ...
Support Center